The rationale for targeting L. iners rather than simply eliminating all bacteria rests on a growing body of ecological evidence. Vaginal communities are classified into five major community state types, with CST I dominated by L. crispatus and CST III dominated by L. iners. Although CST III also occurs in asymptomatic women, L. iners-dominated communities have been associated with greater Candida colonization, reduced clearance of high-risk human papillomavirus infection and, in specific cohorts, poorer in vitro fertilization outcomes. Reduced L. crispatus abundance, meanwhile, has been linked to spontaneous preterm birth. Because bacterial vaginosis recurrence remains common after metronidazole therapy and post-treatment communities frequently remain or become dominated by L. iners, the post-antibiotic interval represents a strategic window in which ecological steering toward L. crispatus dominance might be achievable.

The researchers began with metabolic profiling. Using API 50 CH carbohydrate strips across five strains of each Lactobacillus species, they found that L. crispatus displayed broader, strain-dependent carbohydrate utilization, while all five L. iners strains fermented only glucose and maltose and none utilized galactose, xylose or raffinose. This raised the possibility of prebiotic selectivity: substrates that L. crispatus could exploit but L. iners could not. However, when galactose, xylose and raffinose were tested in monocultures, all five L. iners strains reached comparable viable counts, meaning the carbohydrates provided insufficient selectivity to favour L. crispatus under the nutrient-rich conditions tested. The authors report this negative result candidly, noting that alternative excipients such as alginate, sucrose and trehalose, which have shown promise in other studies, warrant further comparative evaluation.

A striking incidental finding emerged from the culture work: when defibrinated horse blood was omitted from the growth medium, none of the five L. iners strains could replicate. This observation, consistent with the species’ known cysteine dependence and predicted heme-associated functions, suggested that L. iners relies on blood-derived nutrients, including heme-associated iron. The team therefore turned to nutritional restriction as a selective strategy, selecting Vitis vinifera-derived oligomeric proanthocyanidins (OPCs), which can sequester iron, amino acids and peptides, and ethylenediaminetetraacetic acid (EDTA), a metal chelator with established antibiofilm credentials. In simulated vaginal fluid supplemented with 3% boric acid, 0.25% OPCs, 0.05% EDTA and 0.5% raffinose, L. iners viability fell by approximately 3 log10 CFU/mL over 48 hours, while most L. crispatus strains were affected far less. Subsequent compatibility screening identified 0.25% OPCs plus 0.05% EDTA as the combination least inhibitory to L. crispatus.

The decisive selectivity, however, came from fatty acids. Testing oleic, linoleic and palmitoleic acids by broth microdilution, the researchers found that oleic acid offered the widest differential between the two lactobacilli. For L. iners DSM 13335, the minimum inhibitory and bactericidal concentrations were 0.4 and 0.8 mM respectively, whereas the corresponding endpoints for three L. crispatus strains ranged from 1.6 mM to beyond 6.4 mM, the highest concentration tested. Linoleic and palmitoleic acids inhibited both species within a narrower window. The mechanistic explanation, drawn from prior work, is elegant: L. crispatus possesses the oleate hydratase OhyA and a putative fatty-acid efflux protein, FarE, which together support fatty-acid utilization and tolerance, while L. iners lacks these functions. Oleic acid thus acts as an ecological selector rather than a blunt antimicrobial.

When the full three-component mixture of 0.25% OPCs, 0.05% EDTA and 6.4 mM oleic acid was challenged against vaginal microorganisms for 24 hours, the results were pronounced. L. iners counts fell by approximately 4.8 log10 CFU/mL relative to controls, while the three L. crispatus strains showed only 0.3 to 0.5 log10 CFU/mL reductions that were not statistically significant. All four clinically relevant Candida species tested, C. albicans, C. glabrata, C. krusei and C. parapsilosis, showed significant reductions of roughly 1.4 to 2.5 log10 CFU/mL, even though individual fatty acids alone had shown no fungicidal activity at the concentrations tested, suggesting that component interactions, antiadhesive effects or antibiofilm mechanisms may underlie the antifungal activity. Cytotoxicity testing in HeLa cells showed no significant increase in lactate dehydrogenase release at dilutions of 1.56 to 12.5% of the undiluted preparation, but significant, concentration-dependent membrane damage appeared at 25 to 100%, highlighting that an overlapping active and cytocompatible exposure window has yet to be established.

The second module of the study addressed direct fungal suppression through statin chemistry. Monacolin K is chemically identical to lovastatin, and its β-hydroxy acid form, monacolin KA, directly inhibits HMG-CoA reductase in the fungal mevalonate pathway, restricting ergosterol synthesis. In overnight assays, purified monacolin KA showed the broadest antifungal activity, reducing C. albicans counts by approximately 4.3 log10 CFU/mL at 50 µg/mL, with C. albicans and C. glabrata particularly responsive and C. krusei less susceptible, a pattern consistent with known species-dependent statin responses. Monacolin K showed a narrower spectrum, active against C. albicans, C. glabrata and C. parapsilosis. Critically, both compounds preserved high L. crispatus viability at the tested concentrations, with M247, SS and DC reaching counts of 8.34 to 8.88 log10 CFU/mL at 25 to 50 µg/mL. By testing purified compounds rather than complex red-yeast-rice preparations, the authors avoided confounding by other fermentation metabolites and identified monacolin KA as the priority antifungal candidate.

Translational support came from an exploratory longitudinal observation of a 32-year-old woman undergoing assisted reproductive treatment, reported under the CARE guidelines. Her vaginal microbiota initially showed a CST I profile with L. crispatus at roughly 95% relative abundance, but symptomatic bacterial vaginosis in April 2024 shifted the community to CST IV. After intravaginal and oral metronidazole, the profile became CST III, with L. iners accounting for 99.087% of the community. Following recurrent Gardnerella dominance, an intravaginal prototype containing 0.25% OPCs and 0.05% EDTA in an extra-virgin olive-oil vehicle was introduced alongside continued oral L. crispatus M247 supplementation and a short boric acid course. Over the following months, L. crispatus rose from 0.020% to 5.695%, then 25.341%, 68.338% and finally 96.862% by April 2026, at which point the community had returned to CST I, Gardnerella was undetectable, L. iners accounted for only 0.337% and the patient was asymptomatic. No treatment-related adverse events were reported.

The authors are careful to emphasize the limitations of this clinical signal. The prototype differed from the laboratory mixture containing free oleic acid, and the concomitant treatments preclude any attribution of the microbiota transition to the prototype alone. The evidence base remains predominantly in vitro, no animal studies were performed, and only a single clinical observation is available. Short-term monocultures cannot reproduce epithelial interactions, hormonal variation, multispecies biofilms, local retention or repeated exposure, and effects on the CST IV-associated bacteria that drive bacterial vaginosis require direct evaluation. Cytocompatibility also needs refinement, with further assessment planned in non-transformed vaginal epithelial cells or reconstructed vaginal tissue, including repeated exposures and measurements of barrier integrity.

Nevertheless, the study lays out a coherent blueprint for a new generation of intravaginal formulations that work with vaginal ecology rather than against it. The bacterial-selective module could serve as an adjunctive or post-antibiotic therapy for bacterial vaginosis, targeting the frequent emergence of L. iners during recovery, and the association between CST III and reduced HPV clearance provides a rationale for future studies of whether microbiota modulation affects viral persistence. The monacolin module targets settings where Candida colonization or recurrent vulvovaginal candidiasis predominates, a condition with a substantial global burden. Ongoing work is exploring a standardized, fractionated Pistacia lentiscus berry oil rich in oleic acid as a natural alternative to purified oleic acid, potentially extending activity to Streptococcus agalactiae, and reassessing boric acid inclusion. The next steps, standardized manufacture, stability studies, polymicrobial vaginal models and controlled clinical comparisons, will determine whether this laboratory selectivity can translate into sustained L. crispatus dominance in patients.

Subject of Research: Selective modulation of the vaginal microbiota to suppress Lactobacillus iners and Candida while preserving Lactobacillus crispatus

Article Title: Vaginal formulations selectively target Lactobacillus iners and Candida spp. while preserving Lactobacillus crispatus

Article References: Di Pierro, F., Sagheddu, V., Galletti, S., Casaroli, A., Soldi, S., Bertuccioli, A., Palazzi, C. M., Senatori, R., Carugno, A., Antipov, M. O., Briko, N. I., & Zerbinati, N. (2026). Vaginal formulations selectively target Lactobacillus iners and Candida spp. while preserving Lactobacillus crispatus. International Microbiology. https://doi.org/10.1007/s10123-026-00906-0

Image Credits: AI Generated

DOI: 10.1007/s10123-026-00906-0

Keywords: vaginal microbiota, Lactobacillus crispatus, Lactobacillus iners, Candida, oleic acid, oligomeric proanthocyanidins, EDTA, monacolin KA, bacterial vaginosis, community state types, probiotics, antifungal